Efficacy and Safety Data for Tavapadon as an Emerging Therapy in Parkinson’s Disease

The expert faculty reviews the clinical evidence supporting tavapadon from the TEMPO 1, TEMPO 2, and TEMPO 3 trials in Parkinson’s disease. The TEMPO 1 and TEMPO 2 studies evaluated tavapadon as monotherapy in newly diagnosed patients and demonstrated significant improvements in motor symptoms as measured by the Unified Parkinson’s Disease Rating Scale, with efficacy appearing comparable to levodopa and stronger than older dopamine agonists. The TEMPO 3 study assessed tavapadon as an adjunct to levodopa and showed increased “on” time, reduced “off” time, and less troublesome dyskinesia. These findings suggest that tavapadon may help control symptoms without requiring higher levodopa doses, which are associated with motor fluctuations, dyskinesia, and orthostatic hypotension. Overall, the data suggest that this once-daily, long–half-life dopamine agonist could become an attractive option both as monotherapy and as adjunctive therapy in Parkinson’s disease.